Joseph Y. Chang - Jun 1, 2022 Form 4 Insider Report for NU SKIN ENTERPRISES, INC. (NUS)

Role
Chief Scientific Officer
Signature
/s/ Gregory Belliston as Attorney-in-Fact for Joseph Y. Chang
Stock symbol
NUS
Transactions as of
Jun 1, 2022
Transactions value $
-$254,978
Form type
4
Date filed
6/2/2022, 06:15 PM
Previous filing
Mar 3, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUS Class A Common Stock Options Exercise $490K +16K +69.7% $30.63 39K Jun 1, 2022 Direct
transaction NUS Class A Common Stock Sale -$415K -8.98K -23.04% $46.25 30K Jun 1, 2022 Direct F1, F2
transaction NUS Class A Common Stock Sale -$330K -7.03K -23.43% $46.97 23K Jun 1, 2022 Direct F1, F3
holding NUS Class A Common Stock 78.1K Jun 1, 2022 Held in irrevocable family trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUS Employee Stock Option (Right to Buy) Options Exercise $0 -16K -37.56% $0.00 26.6K Jun 1, 2022 Class A Common Stock 16K $30.63 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.77 to $46.75, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.81 to $47.25, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F4 This report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F5 Currently exercisable in full.